This study aims to 1) determine the feasibility, initial signal, and safety with 6 weeks of IV ketamine versus midazolam in individuals with MUD and 2) evaluate the efficacy and safety of ketamine compared to midazolam during an additional 6 weeks of the observational follow-up period.
CTN Protocol ID:
CTN-0132
Status:
Development
Principal Investigator(s)
Madhukar H. Trivedi, M.D.
Betty Jo Hay Distinguished Chair in Mental Health Professor, Node Principal Investigator
University of Texas Southwestern Medical Center
Department of Psychiatry
5323 Harry Hines Boulevard
Dallas, TX 75390
United States